<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216355</url>
  </required_header>
  <id_info>
    <org_study_id>MDS-SCT-01</org_study_id>
    <nct_id>NCT04216355</nct_id>
  </id_info>
  <brief_title>Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT</brief_title>
  <official_title>The Feasibility of a Bridging Treatment With Low-dose Azacitidine (AZA) in Combination With Short Term CAG Derived Regimen Prior to Allogeneic Stem Cell Transplantation (Allo-HSCT) in Patients With Advanced Myelodysplastic Syndromes (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single arm, prospective study on the feasibility of a bridging treatment with low-dose
      azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem
      cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Time to Engraftment</measure>
    <time_frame>Baseline to engraftment, assessed minimally 28 days post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Graft-versus Host Disease</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic infections</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>MDS-EB</condition>
  <arm_group>
    <arm_group_label>AZA with CAG derived regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine 50mg/m²/day, D1-D5 (IV) Aclarubicin 5mg/m²/day, D1-D4 (IV) Cytarabine 10mg/m²/12h, D1-D6 (IV) G-CSF 5-10ug/kg/day, D1-D7 (SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Low-dose AZA</description>
    <arm_group_label>AZA with CAG derived regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAG Protocol</intervention_name>
    <description>Short term CAG derived regimen</description>
    <arm_group_label>AZA with CAG derived regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New Diagnosed advanced myelodysplastic syndrome (MDS) for whom an allogeneic
             hematopoietic stem cell transplant is planned

          -  Recipient of an allogeneic hematopoietic stem cell transplantation

          -  Age &lt; 65 years

          -  ECOG performance status ≤2

          -  Written informed consent

          -  No psychological, familial, social, or geographic reason that would compromise
             clinical follow up

        Exclusion Criteria:

          -  Relapsed or refractory advanced MDS

          -  Severe pshyciatric or organic disorder, supposed to be independent from advanced MDS,
             that would contraindicate treatment

          -  Known allergic or hypersensitivity to azacitidine, aclarubicin or cytarabine or to any
             of the test compounds, materials

          -  Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric
             illness which could place the subject at unacceptable risk

          -  A co-morbid condition which, in the view of the Investigators, renders the subject at
             high risk from treatment complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ting Yang, Prof.M.D.Ph.D</last_name>
    <phone>86-591-86218441</phone>
    <email>yang.hopeting@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Yang, Prof.</last_name>
      <phone>+86-591-83357896</phone>
      <phone_ext>8041</phone_ext>
      <email>yang.hopeting@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianda Hu, Prof.</last_name>
      <phone>+86-591-83357896</phone>
      <phone_ext>8041</phone_ext>
      <email>jdhu@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ting Yang, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Ting YANG</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

